Europe - FRA:FME - DE0005785802 - Common Stock
The current stock price of FME.DE is 41.76 EUR. In the past month the price decreased by -10.98%. In the past year, price increased by 3.7%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS.DE | CVS HEALTH CORP | 11.43 | 86.37B | ||
| FRE.DE | FRESENIUS SE & CO KGAA | 14.69 | 27.06B | ||
| V3V.DE | FAMICORD AG | 37.86 | 93.49M | ||
| HI.MI | HEALTH ITALIA SPA | 20.33 | 54.15M |
Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. The company is headquartered in Bad Homburg Vor Der Hohe, Hessen and currently employs 112,445 full-time employees. The firm provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. The company has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. The company develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The company owns, operates, or manages dialysis clinics sells products to other dialysis providers.
FRESENIUS MEDICAL CARE AG
Else-Kroener-Strasse 1
Bad Homburg vor der Hohe HESSEN DE
Employees: 111513
Phone: 4961726090
Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. The company is headquartered in Bad Homburg Vor Der Hohe, Hessen and currently employs 112,445 full-time employees. The firm provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. The company has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. The company develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The company owns, operates, or manages dialysis clinics sells products to other dialysis providers.
The current stock price of FME.DE is 41.76 EUR. The price increased by 1.43% in the last trading session.
FRESENIUS MEDICAL CARE AG (FME.DE) has a dividend yield of 3.09%. The yearly dividend amount is currently 1.19.
FME.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The Revenue of FRESENIUS MEDICAL CARE AG (FME.DE) is expected to grow by 1.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
FRESENIUS MEDICAL CARE AG (FME.DE) currently has 111513 employees.
FRESENIUS MEDICAL CARE AG (FME.DE) has a market capitalization of 24.51B EUR. This makes FME.DE a Large Cap stock.
ChartMill assigns a technical rating of 2 / 10 to FME.DE. When comparing the yearly performance of all stocks, FME.DE is a bad performer in the overall market: 60.94% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to FME.DE. FME.DE has an average financial health and profitability rating.
Over the last trailing twelve months FME.DE reported a non-GAAP Earnings per Share(EPS) of 3.22. The EPS decreased by -0.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.36% | ||
| ROA | 2.1% | ||
| ROE | 4.95% | ||
| Debt/Equity | 0.71 |
25 analysts have analysed FME.DE and the average price target is 49.48 EUR. This implies a price increase of 18.49% is expected in the next year compared to the current price of 41.76.
For the next year, analysts expect an EPS growth of 17.76% and a revenue growth 1.28% for FME.DE